|
|
 |
| Авторизация |
|
|
|
| Поиск по указателям |
|
|
|
|
|
|
|
 |
|
|
|
| Rosenberger W.F., Lachin J.M. — Randomization in Clinical Trials : Theory and Practice |
|
|
|
| Предметный указатель |
Accidental bias 21 66 68—70 80 83 149 151 154 205
Accidental bias, complete randomization 68 70
Accidental bias, Efron's biased coin design 69—70
Accidental bias, permuted block design 68 70
Accidental bias, Random allocation rule 68 70
Accidental bias, truncated binomial design 68 70
Accidental bias, Wei's urn design 69—70
Accrual bias 205
Adaptive designs 170 172 195 200
Adaptive designs, dynamic programming 171
Adaptive designs, Group sequential 178
Adaptive designs, play-the-winner rule 170 204
Adaptive designs, roots in bandit problems 170—171
Adaptive designs, roots in randomization 172
Adaptive designs, roots in sequential stopping problems 171
Adaptive stratification 57; See also Covariate-adaptive randomization
Agarwal, D.K. 185 188
Agresti, A. 96 110 186
Aickin, M. 72—73
Algeri, R. 51
Amnitage, P. 55 63
Analysis of variance 22 118 125 131 134
Ancillarity 90 96 193
Andersen, J.S. 184 186 206 209—210 212—213
Andrews, A.F. 212
Anscombe, F.J. 170 186
Association vs. causation 2
Association vs. causation, criteria for causal relationship 5
Asymptotic normality 36 46 108 193 219—220 222 228—229 232—233 235 240 243 247
Athreya, К.В. 179 186 244 248—250
Atkinson, A.C. 59—63
Autocorrelation 70
Bai, Z.D. 184 186 197 201 244 250
Bain, R.P. 18 33 165 168
Balakrishnan, N. 187
Ball, F.G. 60—61 63
Balsley, J. 13
Bandyopadhyay, U. 184—186 199 201
Banks, D. 168
Barker, A.H. 33
Barker, E. 168
Bartlett, R.H. 209—212
Baseline measurements 53 87 95
Basu's Theorem 193
Basu, D. 89 109—110
Bather, J. 172 186
Bayesian inference 91
Bayesian optimal design 60
Bazin, В. 13
Beck, R.W. 164 167
Begg, С.В. 59 63 200—201 228 241
Bella, M. 50—51
Bellman, R. 171 186
Berger, V.W. 76 83 87—88 94 110 157 67
Berry, D.A. 65 73 170—171 186
Bey, M. 13
Bfflingsley, P. 219 225
Biswas, A. 184—186 199 201
Black, R.E. 14
Blackwell, D. 19 33 40 51 76—77 79 87—88
Bonferroni correction 27
Book of Daniel 3
Branch and bound algorithm 104
Breslow, N.E. 4 13 63 120 122 147
Bristow, M.R. 164 168
Brooks, M.M. 199 202
Brown, B.W. 63 234 241
Brown, С.Н. 167
Buyse, M.E. 2 6 13
Byar, D.P. 208 212
Cairns, J. 8—9 13
Cardiac Arrhythmia Suppression Trial 33
Carson, P.E. 168
Cauchy — Schwartz inequality 224
Censoring 97—98 102 195 199
Central limit theorems, Hajek's 217 231—232
Central limit theorems, Hoist's 216 229—230
Central limit theorems, Lindeberg — Feller 215—216 228
Central limit theorems, martingale 219—220 234—236
Central limit theorems, martingale, Billingsley's 219 221 223—224
Central limit theorems, martingale, Hall and Heyde's 220 236 248
Chalmers, Т.С. 76 88
Charalambides, С.А. 187
Chebyshev's inequality 66—67 218
Chen, Y.-P. 44—45 47 51
Chernoff, H. 171 186
Chi-square test 97 234 244
Chow, S.-C. 13
Chow, S.-J. 2
Chung, K.L. 215 224—225
Cleary, P.A. 164 167
Clinical effectiveness 16 20
Clinical trial 1
Clinical trial, components 2
Clinical trial, controlled 3
Clinical trial, examples, Bladder cancer 166
Clinical trial, examples, Bradford Hill's trials 8
Clinical trial, examples, Cardiac Arrhythmia Suppression Trial 57
Clinical trial, examples, Congestive heart failure 164
Clinical trial, examples, Diabetes Control and Complications Trial 6 19 22 106 144 153 164
Clinical trial, examples, Diabetes Prevention Program 22 153 163 165
Clinical trial, examples, Diabetic nephropathy 17 165
Clinical trial, examples, Extracorporeal Membrane Oxygenation 209
Clinical trial, examples, Fluoxetine 209—210
Clinical trial, examples, Health Insurance Plan Trial 8
Clinical trial, examples, Hypotension and spinal anesthesia 204
Clinical trial, examples, Lupus Nephritis Collaborative Study 6
Clinical trial, examples, Maternal-fetal HIV transmission 10
Clinical trial, examples, National Cooperative Gallstone Study 44
Clinical trial, examples, Neonatal Inhaled Nitric Oxide Study 141
Clinical trial, examples, Optic Neuritis Treatment Trial 164
Clinical trial, examples, Polio vaccine 8
Clinical trial, fixed follow-up duration 24—25
Clinical trial, four phases 6
Clinical trial, multi-center 15 19 53 55—56 76 117 150 152 159 203 206
Clinical trial, placebo-controlled 6
Clinical trial, pragmatic 7
Clinical trial, survival 16 28 31 203
Clinical trial, survival, exponential model 28
Clinical trial, therapeutic 6
Clinical trial, variable follow-up duration 24—25
Coad, D.S. 172 186 193—195 199 201—202
Cocconi, G. 50—51
Cochran, W.G. 22 33
Collaborative Study Group 33
Colton, Т. 170 186
Competing risks 3
Complete randomization 35—37 39 45—46 48—51 56—57 67—68 70 78 96—97 100—101 103—105 108 112 119—121 130—131 137—138 152 154 158 215 227—234 236—237 240
Complete randomization, imbalances 36
Confirmatory analyses 147
Confounding variable 4—5 9
Connor, E.M. 10—11 13
Consent 9 21 76 160 205
Consistency 101 178 222 225 244 246 249
Coombs, R. 13
Cornell, R.G. 209—212
Cornfield, J. 2—3 7 13 170 186 207 212
Covariate imbalances 21 53—54 57 66 70 72 127 150—151 154
Covariate imbalances, bound on probability of 66
Covariate independence assumption 130 134—135 138
Covariate-adaptive randomization 35 57—59 61 72 104—105 130 151 153 247
Covariate-adaptive randomization, Pocock — Simon procedure 58—59 72 104 151 166
Covariate-adaptive randomization, Taves's minimization method 58 72
Covariate-adaptive randomization, Wei's marginal urn design 59
Covariate-adaptive randomization, Zelen's rule 57—59
Cox, D.R. 63 157 167
Cox, G.M. 22 33
Cramer — Wold device 219 223—224
Crone, R.K. 210—212
Crossover design 23
| Culnane, M. 13
Davis, K. 56—57 62—63
Davis, С.S. 135 147
Day, N.E. 4 13
De Lisi, V. 51
Declaration of Helskinki 11
Delfraissy, J.-E. 13
DeMets, D.L. 2 14 16—17 33 36 52 55 63 107 111 212
Di Constanzo, F. 51
Diabetes Control and Complications Trial Research Group 144
Diabetes Prevention Program Research Group 22 33 153 165 168
Dillon, P.W. 12
Donev, A.N. 63
Donner, A. 25 33
Dray, J. 168
Dunnett's procedure 50
Dunnett, С.W. 50—51
Durham, S.D. 173 183 187—188 192 221—222 226 245 250
Echt, D.S. 17 33
Edgington, E.S. 104 110
Efficacy analysis 20
Efron, В. 43 51 58 63 67—70 73 84 88
Eick, S.G. 171 186
Eigenvalue 68—69 151 179—180
Eigenvector 44 68 179—180
Eisele, J.R. 178 187
Eligibility criteria 23 76 95 160
Ellcins, M. 13
Ellenberg, J.H. 212
Empirical science 2
Engelhardt, H.Т. 9 13
Epidemiology 2
Epstein, M.R. 212
Equipoise 9—10 36 169
Ethics, collective 9
Ethics, individual 9
Evans, A.S. 4 14
Exner, D.V. 76
Exploratory analyses 147
Factorial designs 22
Fanes, D.E. 184 206 209—210 212—213
Feldman, A.M. 164 168
Feller, W. 79 88 241
Fisher's Exact Test 38
Fisher's information 102 109 222
Fisher, R.A. 1 13 89 110 157 168
Flehinger, B.J. 172 187
Fleiss, J.L. 118 147—148
Fleming, T.R. 16—17 33 140—141 148
Flournoy, N. 63 170 183 186—188 192 202 221—222 226 250
Flyer, P.A. 123 148
Follow-up schedule 23
Foulkes, M.A. 28—29 33
Francis, Т. 8 13
Frechet derivative 60
Freedman, D. 9 14 248 250
Friedewald, W.T. 212
Friedman, L.M. 2 14 36 52 55 63
Fristedt, В. 170 186
Furberg, С.D. 2 14 36 52 55 63
Gail, M.H. 212
Gani, J. 63
Gastwirth, J.L. 102 110
Gehan — Wilcoxon test 184 199
Gelber, R. 10—11 13
Generalized linear models 244
Geraldes, M. 177—178 188 246—247 250
Gilbert, E.M. 168
Gittins, J.C. 170 187
Good, P. 104 110
Goodness-of-fit statistics 156
Gouws, E. 213
Govindarajulu, Z. 195 201
Grambsch, P.M. 140 148
Greenhouse, S.W. 170 186 207 212
Grizzle, J.E. 126—128 148
Groshen, S. 166
Group sequential monitoring 107
Group sequential monitoring, Lan — DeMets approach 107
Group sequential monitoring, Slud — Wei approach 107—108
Group sequential monitoring, spending function approach 107 109
Haenszel, W. 118 148
Hajek, J. 101 110 217 225 240
Hall, P. 217 219—220 225
Hallstrom, A. 56—57 62—63 199 202
Halperin, M. 170 186 207 212
Halpern, J. 234 241
Halsey, N.A. 11 14
Hardwick, J. 170—171 173 187 200 202
Harper, C.N. 188 202
Harrington, D.P. 140—141 148
Hayre, L.S. 172 174—175 187
Hazard function 28
Hazard rate 29—31
Heckert, A. 168
Heckman, N. 238 241
Henderson, D.A. 11 14
Hendrix, G.H. 168
Heyde, С.С. 217 219—220 225
Historical controls 10
Hodges, J.L. 19 33 40 51 76—77 79 87—88
Hoist, L. 216 225
Hollander, M. 104 110 234 241
Howard, S.V. 63
Hu, F. 184 186 195—197 201—202 207 213 244 250
Hu, M. 244 250
Hunsicker, L.G. 6 14 18 33 165 168
Iglewicz, В. 59 63
Incidence rate 28 31—32
Intention to treat analysis 20—21 150
International Chronic Granulomatous Disease Cooperative Study Group 17 33
Intrablock correlation coefficient 125
Ivanova, A.V. 83 88 157 167 175 177 182—184 187—188 193—194 198—199 201—202 245 250
Jacobsen, R.L. 13
Jennison, C. 107 110 174 178 187
Jimenez, E. 13
Jones, В. 23 33
Juhl, E. 2 14
Kadane, J.В. 91 110
Kalbfleisch, J.D. 97—98 111
Kalish, L.A. 228 241
Karlin, S. 44 52 179 186 244 249
Kaufman, D.I. 167
Kelsey, J.L. 4 14
Kelton, W.D. 156 168
Kenward, M.G. 23 33
Kiefer, J. 60 63
Kiselev, P. 13
Knoll, M.D. 83 88 157 167
Koutras, M.V. 187
Kronecker delta 69 179 238
Kupersmith, M.J. 167
Lachin, J.M. 2 14 18 20 25 28—29 33 37 44—45 52 55 63 92 95 103 109 111 123 125 131 134 142 148 150 152—153 155 168 175 205 213
Laha, R.G. 215 226
Lakatos, E. 28 33
Lan, K.K.G. 107 109 111
Lan, S. 6 14
Landenberger, B.D. 210 212
Law, A.M. 156 168
Lehmann, E.L. 94 110—111 193 202 222 226
Leigh, S. 168
Levenson, M. 168
Levin, J. 204 213
Lewis, E.J. 6 14 18 33 165 168
Lfflehei, С.W. 212
Li, W. 183 187
Liebson, P.R. 17 33
Likelihood 90—91 191—192 221—222 243 245
Likelihood, ratio test 245
Likelihood, response-adaptive randomization 191 193
|
|
|
| Реклама |
|
|
|
|
|
О проекте